Biosimilars offer the promise of cutting edge treatments, but possibly at lower costs. With society pushing for therapies leading to a cure, can this new class of drugs help answer some of cancer’s most challenging problems? How will doctors and patients respond to the increased availability of biosimilars in the US? What has been the general reception regarding clinical use and safety? And how do we navigate the regulatory landscape as we look further afield?
The Atlantic gathered leading experts, oncologists and patients to explore the future of biosimilars in cancer treatment.
This is not an official event of the 2018 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation.
*This speaker participated in a session that was produced by our underwriter and not by The Atlantic's editorial team.
**This session was produced by our underwriter and not The Atlantic's editorial team.
Attendance at our events constitutes acceptance of our Code of Conduct (effective 1/2/2018) and Privacy Policy (effective 1/2/2018).
AtlanticLIVE Copyright (c) 2018 by The Atlantic Monthly Group. All Rights Reserved.